This study investigates whether adding an investigational medication to the usual treatment can lower the chances of acute myeloid leukemia (AML) returning or worsening. AML is a type of cancer that affects the blood and bone marrow, where blood cells are made. The study aims to find out if the additional treatment can improve outcomes for patients with AML.

Participants will receive either the standard treatment alone or the standard treatment plus the investigational medication. The study procedures include regular monitoring of health and responses to the treatment. A placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine, may be used for comparison.

• Who can participate: Adults diagnosed with acute myeloid leukemia (AML) according to the 2017 WHO criteria can participate, except those with acute promyelocytic leukemia with PML-RARA. Participants must not have AML involvement in the central nervous system.
• Study details: Participants will be assigned to receive either the usual treatment alone or in combination with the investigational medication. A placebo may be used for comparison, which is an inactive substance that looks like the investigational medication but does not contain any medicine.